BioSig Technologies to Acquire PediaQ for $10M
Ticker: STEX · Form: 8-K · Filed: Jul 24, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Jul 24, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pediatric-care
TL;DR
BioSig buying PediaQ for $10M to boost pediatric offerings. Deal expected Q3.
AI Summary
BioSig Technologies, Inc. announced on July 23, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of PediaQ, Inc. for an aggregate purchase price of $10 million. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition aims to expand BioSig's product offerings and market reach in the pediatric care sector.
Why It Matters
This acquisition could significantly expand BioSig's presence in the pediatric healthcare market, potentially leading to increased revenue and market share.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overvaluation, and failure to achieve expected synergies.
Key Numbers
- $10.0M — Acquisition Price (Aggregate purchase price for PediaQ, Inc.)
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- PediaQ, Inc. (company) — Acquisition Target
- $10 million (dollar_amount) — Aggregate Purchase Price
- July 23, 2024 (date) — Agreement Date
- third quarter of 2024 (date) — Expected Closing Period
FAQ
What is the primary strategic rationale behind BioSig's acquisition of PediaQ?
The acquisition is intended to expand BioSig's product offerings and market reach, particularly within the pediatric care sector.
What is the total value of the transaction to acquire PediaQ?
The aggregate purchase price for all outstanding shares of PediaQ, Inc. is $10 million.
When is the acquisition of PediaQ expected to be completed?
The transaction is anticipated to close in the third quarter of 2024, subject to customary closing conditions.
What is the legal structure of the PediaQ acquisition?
BioSig Technologies, Inc. has entered into a definitive agreement to acquire all outstanding shares of PediaQ, Inc.
Are there any specific conditions that must be met for the PediaQ acquisition to close?
Yes, the transaction is subject to customary closing conditions.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-07-24 13:05:25
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-24-028895.txt ( ) — 202KB
- bsgm-20240723.xsd (EX-101.SCH) — 3KB
- bsgm-20240723_lab.xml (EX-101.LAB) — 33KB
- bsgm-20240723_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: July 24, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer